Randomized, placebo-controlled, double-blind, parallel design, Phase 3 study to evaluate the
safety and efficacy of udenafil, an orally administered, potent and selective inhibitor of
PDE-5 versus placebo for the treatment of subjects with erectile dysfunction (ED).